Recent from talks
Pentosan polysulfate
Knowledge base stats:
Talk channels stats:
Members stats:
Pentosan polysulfate
Pentosan polysulfate, sold under the brand name Elmiron among others, is a medication used for interstitial cystitis. Evidence of benefit, however, is mixed as of 2024. It is recommended that the medication be stopped if there is no improvement within 6 months. It was approved for medical use in the United States in 1996.
Pentosan polysulfate sodium is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. Evidence of benefit, however, is mixed as of 2024 with some studies finding benefit and others not.
People who have taken pentosan polysulfate by mouth report a variety of side effects, primarily gastrointestinal complaints such as diarrhea, heartburn, and stomach pain. Hair loss, headache, rash, and insomnia have also been reported. Due to anticoagulant effects, some report bruising more easily. In some cases, people are asked to stop taking the medication before major surgery to reduce the likelihood of bleeding.
Pentosan polysulfate maculopathy (PPSM) is a slowly worsening eye condition that affects the retinal pigment epithelium (RPE) and can lead to vision problems. It has been strongly linked to long-term use of pentosan polysulfate sodium (PPS), a drug commonly prescribed for interstitial cystitis.
A 2025 review of data from over 140,000 patients found that the risk of developing PPSM increases with the total amount of PPS taken, with a 0.1% rise in relative risk for each gram of the drug used. People who took at least 2000 grams of PPS (roughly equal to 18 years of typical treatment) had a 8 times higher risk of developing PPSM than non-users, while even low exposures (<500g) were linked to a 2 times higher risk. Multimodal imaging techniques can detect specific signs of the condition, such as mottled areas in the RPE, patches of abnormal autofluorescence, and deposits beneath the retina. These features can help distinguish PPSM from inherited maculopathies with >99% accuracy.
Even after stopping the drug, about 20% of people continue to show worsening changes in the macula, which is why baseline and yearly eye exams—including optical coherence tomography and fundus autofluorescence—if PPS has been used. Current recommendations advise reducing the PPS dose to the lowest amount that reduces symptoms and watching carefully for early signs of eye damage.
In interstitial cystitis, pentosan polysulfate is believed to work by providing a protective coating to the damaged bladder wall. Pentosan polysulfate is similar in structure to the natural glycosaminoglycan coating of the inner lining of the bladder, and may replace or repair the lining, reducing its permeability.
The calcium salt of pentosan polysulfate was one of the first reported disease-modifying osteoarthritis drugs (DMOAD).
Hub AI
Pentosan polysulfate AI simulator
(@Pentosan polysulfate_simulator)
Pentosan polysulfate
Pentosan polysulfate, sold under the brand name Elmiron among others, is a medication used for interstitial cystitis. Evidence of benefit, however, is mixed as of 2024. It is recommended that the medication be stopped if there is no improvement within 6 months. It was approved for medical use in the United States in 1996.
Pentosan polysulfate sodium is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. Evidence of benefit, however, is mixed as of 2024 with some studies finding benefit and others not.
People who have taken pentosan polysulfate by mouth report a variety of side effects, primarily gastrointestinal complaints such as diarrhea, heartburn, and stomach pain. Hair loss, headache, rash, and insomnia have also been reported. Due to anticoagulant effects, some report bruising more easily. In some cases, people are asked to stop taking the medication before major surgery to reduce the likelihood of bleeding.
Pentosan polysulfate maculopathy (PPSM) is a slowly worsening eye condition that affects the retinal pigment epithelium (RPE) and can lead to vision problems. It has been strongly linked to long-term use of pentosan polysulfate sodium (PPS), a drug commonly prescribed for interstitial cystitis.
A 2025 review of data from over 140,000 patients found that the risk of developing PPSM increases with the total amount of PPS taken, with a 0.1% rise in relative risk for each gram of the drug used. People who took at least 2000 grams of PPS (roughly equal to 18 years of typical treatment) had a 8 times higher risk of developing PPSM than non-users, while even low exposures (<500g) were linked to a 2 times higher risk. Multimodal imaging techniques can detect specific signs of the condition, such as mottled areas in the RPE, patches of abnormal autofluorescence, and deposits beneath the retina. These features can help distinguish PPSM from inherited maculopathies with >99% accuracy.
Even after stopping the drug, about 20% of people continue to show worsening changes in the macula, which is why baseline and yearly eye exams—including optical coherence tomography and fundus autofluorescence—if PPS has been used. Current recommendations advise reducing the PPS dose to the lowest amount that reduces symptoms and watching carefully for early signs of eye damage.
In interstitial cystitis, pentosan polysulfate is believed to work by providing a protective coating to the damaged bladder wall. Pentosan polysulfate is similar in structure to the natural glycosaminoglycan coating of the inner lining of the bladder, and may replace or repair the lining, reducing its permeability.
The calcium salt of pentosan polysulfate was one of the first reported disease-modifying osteoarthritis drugs (DMOAD).
Recent media